Emerging role of interleukin‐31 and interleukin‐31 receptor in pruritus in atopic dermatitis
Allergy2017Vol. 73(1), pp. 29–36
Citations Over TimeTop 1% of 2017 papers
Abstract
Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder associated with skin barrier dysfunction. The lesional skin of AD exhibits T helper 2 (TH 2)-deviated immune reactions. Interleukin-31 (IL-31), preferentially produced from TH 2 cells, is a potent pruritogenic cytokine, and its systemic and local administration induces scratching behavior in rodents, dogs and monkeys. Recent clinical trials have revealed that administration of an anti-IL-31 receptor antibody significantly alleviates pruritus in patients with AD. In this review, we summarize recent topics related to IL-31 and its receptor with special references to atopic itch.
Related Papers
- → Atopic dermatitis phenotypes and the need for personalized medicine(2017)154 cited
- → Allergic march in children: Atopic dermatitis in Japanese children with bronchial asthma(1996)5 cited
- Expression and significance of interleukin 4 in patients with atopic dermatitis(2009)
- → A Systemic Review of Dupilumab Efficacy and Safety by Phenotypic Variations of Atopic Dermatitis(2021)
- → Staphylococcus aureus-induced cytokines cause aberrant lipid compositions and skin barrier dysfunction in children with atopic dermatitis(2022)